Polymorphisms rs763110 in FASL is linked to hepatitis C virus infection among high-risk populations

References

• Liu CR, Li X, Chan PL, et al. Prevalence of hepatitis C virus infection among key populations in China: A systematic review. Int J Infect Dis. 2019;80:16–27.
   PubMed Web of Science ®Google Scholar
• WHO, Global hepatitis report 2017 http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
   Google Scholar
• Shchanitcyna S, Burnevich E, Nikulkina E, et al. Risk factors of unfavorable prognosis of chronic hepatitis C. Terapevticheskii Arkhiv. 2019;91:59–66.
   PubMed Web of Science ®Google Scholar
• Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection? Semin Liver Dis. 2014;34:79–88.
   PubMed Web of Science ®Google Scholar
• Matsuura K, Tanaka Y. Host genetic variations associated with disease progression in chronic hepatitis C virus infection. Hepatol Res. 2018;48:127–133.
   PubMed Web of Science ®Google Scholar
• Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, et al. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6.
   PubMed Web of Science ®Google Scholar
• O’Brien TR, Yang H-I, Groover S, et al. Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression. Gastroenterology. 2019;156:400–417.
   PubMed Web of Science ®Google Scholar
• Craxì A, Pawlotsky JM, Wedemeyer H, et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–264.
   Google Scholar
• Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–1444.
   PubMed Web of Science ®Google Scholar
• Wauquier N, Becquart P, Padilla C, et al. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4:e837.
   PubMed Web of Science ®Google Scholar
• Wajant H. The Fas signaling pathway: more than a paradigm. Science. 2002;296:1635–1636.
   PubMed Web of Science ®Google Scholar
• Bien K, Sokolowska J, Baska P, et al. Fas/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungs. Mediators Inflamm. 2015;2015:281613.
   PubMed Web of Science ®Google Scholar
• Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol. 2007;13:4865.
   PubMed Web of Science ®Google Scholar
• Bortolami M, Kotsafti A, Cardin R, et al. Fas/FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat. 2008;15:515–522.
   PubMed Web of Science ®Google Scholar
• El-Mesery M, El-Mowafy M, Elgaml A, et al. Correlation of serum soluble fibrinogen-like protein 2 with soluble FAS ligand and interferon gamma in Egyptian hepatitis C virus-infected patients and hepatocellular carcinoma patients. J Interferon Cytokine Res. 2017;37:342–347.
   PubMed Web of Science ®Google Scholar
• Khalifa RH, Shahin RMH, Aboukhalil REE, et al. Digging more in the genetic risk prediction of hepatitis C virus epidemic in Egypt: apoptosis genes polymorphisms in the susceptibility of hepatitis C virus and association with viral load. Virus Res. 2017;238:35–39.
   PubMed Web of Science ®Google Scholar
• Huang D, Xiao J, Deng X, et al. Association between Fas/FasL gene polymorphism and musculoskeletal degenerative diseases: a meta-analysis. BMC Musculoskelet Disord. 2018;19:137.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae S-C, Song GG. Association between the CTLA-4, CD226, FAS polymorphisms and rheumatoid arthritis susceptibility: A meta-analysis. Hum Immunol. 2015;76:83–89.
   PubMed Web of Science ®Google Scholar
• Fang HUI, Luo X, Wang YAN, et al. Correlation between single nucleotide polymorphisms of the ACTA2 gene and coronary artery stenosis in patients with type 2 diabetes mellitus. Exp Ther Med. 2014;7:970–976.
   PubMed Web of Science ®Google Scholar
• Embryol RJM. Association of the blood serum cytokines’ rate and lymphocytes’ apoptosis with polymorphic variants of the BCL-2 (rs17759659), CTLA-4 (rs231775) and APO-1/FAS (rs2234767) genes in patients with nodular goiters in autoimmune thyroiditis and thyroid adenoma. Rom J Morphol Embryol. 2017;58:931–939.
   PubMed Web of Science ®Google Scholar
• Seo J, Lee EW, Shin J, et al. K6 linked polyubiquitylation of FADD by CHIP prevents death inducing signaling complex formation suppressing cell death. Oncogene. 2018;37:4994–5006.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhou X, Jiang F, et al. FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects. PLoS One. 2013;8:e74543.
   PubMed Web of Science ®Google Scholar
• Hermes RB, Santana BB, Lima SS, et al. FAS −670 A/G polymorphism may be associated with the depletion of CD4(+) T lymphocytes in HIV-1 infection. Hum Immunol. 2015;76:742–746.
   PubMed Web of Science ®Google Scholar
• Karbasi A, Borhani N, Daliri K, et al. Downregulation of external death receptor genes FAS and DR5 in colorectal cancer samples positive for human papillomavirus infection. Pathol Res Pract. 2015;211:444–448.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC, Song GG. Association between the CTLA-4, CD226, FAS polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Hum Immunol. 2015;76:83–89.
   PubMed Web of Science ®Google Scholar
• Yu H, Luo L, Wu L, et al. FAS gene copy numbers are associated with susceptibility to behcet disease and VKH syndrome in Han Chinese. Hum Mutat. 2015;36:1064–1069.
   PubMed Web of Science ®Google Scholar
• Abed S, El-Dosoky M, El Sayed Zaki M, et al. Genetic polymorphisms of Fas/FasL promoter associated with hepatitis C cirrhosis and HCC. Asian Pac J Cancer Prev. 2017;18:2683–2688.
   PubMedGoogle Scholar
• Bortolami M, Kotsafti A, Cardin R, et al. Fas/FasL system, IL-1β expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat. 2008;15:515–522.
   PubMed Web of Science ®Google Scholar
• Sung WW, Wang YC, Cheng YW, et al. A polymorphic −844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res. 2011;17:5991–5999.
   PubMed Web of Science ®Google Scholar
• Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170:132–138.
   PubMed Web of Science ®Google Scholar
• Wu S, Wang S, Fu Y, et al. A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of C/EBPbeta and OCT1 complex to chromatin. Int J Cancer. 2017;140:756–763.
   PubMed Web of Science ®Google Scholar
• Zekri A, Sobhy E, Hussein N, et al. E1/E2 of hepatitis c virus genotype4 and apoptosis. Asian Pac J Cancer Prev. 2016;17:3131–3138.
   PubMedGoogle Scholar
• Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824–7840.
   PubMed Web of Science ®Google Scholar